Premium
Renal Osteodystrophy in Children Treated with 1,25‐Dihydroxy‐Cholecalciferol [1,25‐(OH) 2 D 3 ]: Histologic Bone Studies
Author(s) -
ROBITAILLE PIERRE,
MARIE PIERRE J.,
DELVIN EDGARD E.,
LORTIE LOUISE,
GLORIEUX FRANCIS H.
Publication year - 1984
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1994.tb17741.x
Subject(s) - medicine , osteomalacia , osteodystrophy , renal osteodystrophy , hyperparathyroidism , bone disease , vitamin d and neurology , cholecalciferol , pediatrics , gastroenterology , surgery , kidney disease , osteoporosis
. Eleven uremic children with osteodystrophy aged 3 to 17 years were studied during administration of l, 25‐(OH) 2 D, for periods up to 21 months. Nine children presented with pure hyperparathyroidism, one with osteomalacia and one with mixed bone disease. Bone biopsies were performed before initiation of therapy and after 6 to 21 months of treatment following double tetracycline labeling. Skeletal lesions were improved but not cured in 5 of 9 children with hyperparathyroidism. In three instances lesions remained unchanged and worsened in one. No significant change was observed in the child with osteomalacia. Moderate improvement was noted in the patient with mixed bone disease. The propensity to develop hypercalcemia was the major factor associated with treatment failure since it precluded administration of adequate amounts of medication. Therapy with l, 25‐(OH) 2 D 3 was associated with a spectacular improvement in growth velocity in two of six children under age twelve.